Get the Stockscreener App
51.13
4.11%
-2.19
After Hours:
50.94
-0.19
-0.37%
Cytokinetics Inc stock is traded at $51.13, with a volume of 1.90M.
It is down -4.11% in the last 24 hours and up +49.02% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$53.32
Open:
$52.65
24h Volume:
1.90M
Relative Volume:
1.04
Market Cap:
$6.12B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-9.7205
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-3.55%
1M Performance:
+49.02%
6M Performance:
+16.23%
1Y Performance:
-5.42%
1-Day Range:
$51.06
$53.28
1-Week Range:
$50.05
$54.22
52-Week Range:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
51.13 | 6.22B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics (NASDAQ:CYTK) EVP Sells 2,000 Shares - MarketBeat
Pentwater Capital Management LP Sells 229,100 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Alliancebernstein L.P. Has $61.23 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Alyeska Investment Group L.P. Has $3.01 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential? - Yahoo Finance
Zimmer Partners LP Acquires 44,132 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
15,991 Shares in Cytokinetics, Incorporated $CYTK Bought by Graham Capital Management L.P. - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $75.38 Average PT from Analysts - MarketBeat
Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Why Are These Biotech Stocks Outperforming Their Peers? - CMC Markets
52,321 Shares in Cytokinetics, Incorporated $CYTK Purchased by Cinctive Capital Management LP - MarketBeat
Cutter Capital Management LP Buys Shares of 175,000 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics at Morgan Stanley Conference: Aficamten’s Launch Strategy - Investing.com
Aug Wrap: Can Cytokinetics Incorporated reach all time highs this yearMarket Activity Summary & Free Long-Term Investment Growth Plans - Lancaster City Council
Eventide Asset Management LLC Purchases 128,548 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Incorporated’s Price Action Aligns with Quant Signals2025 Trading Recap & Free Weekly Chart Analysis and Trade Guides - beatles.ru
Investors Purchase Large Volume of Call Options on Cytokinetics (NASDAQ:CYTK) - MarketBeat
Is Cytokinetics Incorporated a top pick in the sectorJuly 2025 Drop Watch & Risk Controlled Swing Alerts - beatles.ru
Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - MSN
Cytokinetics (NASDAQ:CYTK) Price Target Raised to $84.00 at Citigroup - MarketBeat
Will earnings trigger a reversal in Cytokinetics Incorporated2025 Key Highlights & Smart Swing Trading Alerts - Newser
Vestal Point Capital LP Buys 240,531 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Multi asset correlation models including Cytokinetics Incorporated2025 Price Action Summary & Detailed Earnings Play Alerts - Newser
Is Cytokinetics Incorporated’s ROE strong enough2025 Market Outlook & Daily Growth Stock Tips - خودرو بانک
What’s the analyst consensus on Cytokinetics Incorporated2025 Key Highlights & AI Driven Price Predictions - خودرو بانک
Is Cytokinetics Incorporated stock a good pick for beginners2025 Sector Review & Smart Money Movement Tracker - خودرو بانک
Published on: 2025-09-05 22:58:57 - خودرو بانک
Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal - BioWorld MedTech
Is Cytokinetics Incorporated stock bottoming outTrade Signal Summary & Safe Capital Allocation Plans - Newser
Cytokinetics patents new MYBPC2 inhibitors - BioWorld MedTech
Cytokinetics shares rise 1.19% premarket after Cantor Global Healthcare Conference fireside chat. - AInvest
Predicting Cytokinetics Incorporated trend using moving averagesJuly 2025 Patterns & Safe Entry Momentum Tips - Newser
Real time social sentiment graph for Cytokinetics IncorporatedMarket Movement Recap & AI Powered Market Entry Strategies - Newser
Updated: Hengrui does another US deal, this time in Cytokinetics' cardio arena - Endpoints News
858,664 Shares in Cytokinetics, Incorporated $CYTK Bought by Paradigm Biocapital Advisors LP - MarketBeat
Using Python tools to backtest Cytokinetics Incorporated strategiesJuly 2025 Sector Moves & Weekly Market Pulse Updates - Newser
Spinal Muscular Atrophy Market Positioned for Accelerated - openPR.com
Will Cytokinetics Incorporated benefit from macro trendsQuarterly Trade Report & Technical Pattern Recognition Alerts - Newser
Cytokinetics Incorporated stock prediction for this weekJuly 2025 PreEarnings & Consistent Profit Trading Strategies - Newser
How to read the order book for Cytokinetics Incorporated2025 Short Interest & Community Consensus Picks - Newser
How to manage a losing position in Cytokinetics IncorporatedJuly 2025 News Drivers & Proven Capital Preservation Tips - Newser
Movement Recap: Is Cytokinetics Incorporated a top pick in the sector2025 Trading Volume Trends & AI Based Trade Execution Alerts - خودرو بانک
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results - Yahoo Finance
Cytokinetics: Evercore ISI Group raises PT to $80 from $60, maintains Outperform. - AInvest
Cytokinetics shares fall 1.15% premarket after insider sold shares worth $337,800. - AInvest
Will Cytokinetics Incorporated benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - خودرو بانک
Understanding Cytokinetics Incorporated’s price movement2025 Biggest Moves & Community Trade Idea Sharing Platform - Newser
Does Cytokinetics Incorporated show high probability of reboundJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Can Cytokinetics Incorporated recover in the next quarterMarket Rally & Free Safe Capital Growth Stock Tips - Newser
Cytokinetics, Incorporated $CYTK Shares Sold by Rafferty Asset Management LLC - MarketBeat
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):